Clinical Trial Update: Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of two doses of aclidinium bromide versus placebo in chronic obstructive pulmonary disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Aclidinium bromide (Aclidinium bromide)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2012-09-17